Arrowhead Pharmaceuticals, Inc. (ARWR) Income Statement

The extreme quarter-to-quarter variability suggests revenue is not recurring but tied to discrete partnership events. The 171% growth in 2026Q3 is misleading as it follows a depressed prior-year quarter; the underlying trend is unstable. Investors should monitor the pipeline for sustainable product revenue rather than episodic collaborations.

The 100% gross margin is not indicative of pricing power but rather the absence of manufacturing costs in the income statement. With no product revenue, gross margin is meaningless; the real cost burden lies in R&D, which consumed $198.2M in 2026Q3. This structure implies that any future product launch will introduce COGS and compress reported margins.

The company's operating leverage is highly sensitive to revenue recognition from partnerships; when revenue is absent, operating losses deepen due to fixed R&D. The 2025Q2 quarter showed positive operating leverage, but it was unsustainable. The lack of SG&A scaling suggests management is controlling overhead, yet R&D is the primary cost driver and shows no sign of tapering.

The aggressive R&D investment suggests a clinical-stage pipeline with multiple programs, but it also means the company is burning cash at an increasing rate. SG&A has grown more slowly, indicating cost control in administrative areas, but R&D is the strategic priority. The sustainability of this spending depends on future partnership milestones or regulatory approvals.

This quarter demonstrates the potential for high profitability when partnership milestones are recognized, but it also highlights the volatility of the business model. The subsequent quarters reverted to losses, indicating that such inflections are not recurring. The lasting impact is a higher revenue base for comparison, but the company remains dependent on external events for profitability.